Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
38.81
+0.95 (2.51%)
Nov 22, 2024, 4:00 PM EST - Market closed
Verona Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Verona Pharma stock have an average target of 43.83, with a low estimate of 33 and a high estimate of 64. The average target predicts an increase of 12.93% from the current stock price of 38.81.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verona Pharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $64 | Buy | Maintains | $50 → $64 | +64.91% | Nov 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $36 → $42 | Strong Buy | Maintains | $36 → $42 | +8.22% | Nov 5, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $37 → $44 | Strong Buy | Maintains | $37 → $44 | +13.37% | Nov 5, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $38 → $44 | Strong Buy | Maintains | $38 → $44 | +13.37% | Oct 9, 2024 |
| Wells Fargo | Wells Fargo | Buy Initiates $50 | Buy | Initiates | $50 | +28.83% | Oct 3, 2024 |
Financial Forecast
Revenue This Year
21.34M
Revenue Next Year
139.59M
from 21.34M
Increased by 554.09%
EPS This Year
-1.73
from -0.72
EPS Next Year
-0.28
from -1.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.3M | 198.5M | 380.1M | ||
| Avg | 21.3M | 139.6M | 290.1M | ||
| Low | 11.1M | 102.3M | 237.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 829.9% | 172.3% | ||
| Avg | - | 554.1% | 107.8% | ||
| Low | - | 379.4% | 69.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.30 | 1.05 | 0.02 | ||
| Avg | -1.73 | -0.28 | -0.23 | ||
| Low | -2.21 | -1.14 | -0.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.